VOLITIONRX LTD
VOLITIONRX LTD (VNRX): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.0 months
D/E -1.33 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for VOLITIONRX LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$17.5M
Cash
$3.1M
Quarterly Burn
$5.3M
Runway
2.0 mo
Revenue
$985K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| nu.q cancer | Preclinical |
| nu.q nets | Approved |
Frequently asked questions
How many drug candidates are in VOLITIONRX LTD's pipeline?
VOLITIONRX LTD (VNRX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VOLITIONRX LTD's lead drug candidate?
VOLITIONRX LTD's most advanced tracked candidate is nu.q cancer (Preclinical) for Lung cancer screening, diagnosis, staging, and monitoring.
What is VOLITIONRX LTD's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VOLITIONRX LTD has approximately 2.0 months of cash runway.
What is VOLITIONRX LTD's market capitalization?
VOLITIONRX LTD's market capitalization is approximately $17.5M.
Who is the CEO of VOLITIONRX LTD?
Mr. Cameron Reynolds MBA is the chief executive officer of VOLITIONRX LTD (VNRX).
Get the full picture on VOLITIONRX LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.